Hostname: page-component-848d4c4894-p2v8j Total loading time: 0.001 Render date: 2024-06-01T08:21:05.661Z Has data issue: false hasContentIssue false
  • English
  • Français

Safety of psychotropic medications in people with COVID-19

Published online by Cambridge University Press:  13 August 2021

G. Ostuzzi ,
D. Papola ,
C. Gastaldon  and
C. Barbui
G. Ostuzzi*
Affiliation:
Department Of Neuroscience, Biomedicine And Movement Sciences, University of Verona, Verona, Italy
D. Papola
Affiliation:
Department Of Neuroscience, Biomedicine And Movement Sciences, University of Verona, Verona, Italy
C. Gastaldon
Affiliation:
Neuroscience, Psychological And Psychiatric Science, Science Of Bio Movement, University of Verona, Verona, Italy
C. Barbui
Affiliation:
Department Of Neuroscience, Biomedicine And Movement Sciences, University of Verona, Verona, Italy
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

People with coronavirus disease (COVID-19) may frequently require treatment with psychotropic medications, but the underlying medical condition and possible interaction with medical treatments might pose serious safety issues.

Objectives

To review the direct and indirect evidence on the safety of psychotropic drugs in people with COVID-19 and provide practical recommendations for frontline clinicians.

Methods

An international, multi-disciplinary working group was established with the aim of producing evidence-based recommendations on the management of psychotropic medications in people with COVID-19, following the WHO Rapid Advice Guidelines methodology in the context of a public health emergency. Evidence retrieved was focused on the risk of respiratory, cardiovascular, infective, hemostatic, and consciousness alterations related to the use of psychotropic medications. Furthermore, drug-drug interactions between psychotropic and medical treatments used in people with COVID-19 was reviewed and critically discussed by the working group.

Results

The analysis of available evidence, although indirect, showed that all classes of psychotropic medications might carry relevant safety risks for people with COVID-19. The working group produced a set of 12 recommendations to support clinicians in the assessment of the anticipated risk of psychotropic-related unfavourable events, and how to practically manage this risk, including when it is appropriate to avoid, withdraw, switch, or adjust the dose of the medication.

Conclusions

The present evidence-based recommendations will improve the quality of psychiatric care in people with COVID-19, allowing an appropriate management of the medical condition without worsening the psychiatric condition and vice versa.

Disclosure

No significant relationships.

Keywords

coronavirusCOVID-19Psychopharmacologydrug-drug interaction
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S93
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.